Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit

Philip Bruggmann; Bettina Maeschli

doi:10.4414/smw.2020.20348

Viewpoint

Vol. 150 No. 3738 (2020)

Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit

Philip Bruggmann⁺⁻
Bettina Maeschli⁺⁻

DOI: https://doi.org/10.4414/smw.2020.20348
Cite this as:: Swiss Med Wkly. 2020;150:w20348
Published: 18.09.2020

References

Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour JF, Moradpour D, et al.; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat. 2018;25(2):152–60. doi:.https://doi.org/10.1111/jvh.12803
Schürch S, Fux C, Dehler S, Conen A, Knuchel J, Friedl A, et al. Management of hepatitis C in opioid agonist therapy patients of the Swiss canton Aargau within and outside the cohort study. Swiss Med Wkly. 2020.;150:w20317. doi:. https://doi.org/10.4414/smw.2020.20317
Beck T, Bruggmann P, Haemmig R, Caflisch C, Falcato L, Fink A, et al. Medizinische Empfehlungen für Opioidagonistentherapie (OAT) bei Opioidabhängigkeits-Syndrom 2020. Bern: SSAM; 2020.
Federal Office of Public Health Switzerland. Hepatitis C bei Drogenkonsumierenden. Richtlinien mit settingsspezifischen Factsheets. Bern: 2019. https://www.infodrog.ch/files/content/hepc_de/richtlinien-hepatitis-c-drogen-de-2019.pdf
Kind J, Maeschli B, Bruggmann P. Im Schatten von HIV: Das “Aschenbrödel” Hepatitis C. Suchtmedizin. 2019;21(3):103–10.
Müller D, Dittli J, Eder J, Ettlin E, Janiak C, Stöckli H. Motion 19.3743: Die Eliminierung von Hepatitis gehört in ein Nationales Programm sexuell und blutübertragbarer Infektionskrankheiten. In: EDI, editor. Bern: Die Bundesversammlung - das Schweizer Parlement; 2019.
Hepatitis Schweiz. The HepCare Project: Swiss Hepatitis; 2020: www.hepcare.ch.

Publication image

How to Cite

1.

Bruggmann P, Maeschli B. Hepatitis C micro-elimination among people on opioid agonist therapy is a low-hanging fruit. Swiss Med Wkly [Internet]. 2020 Sep. 18 [cited 2024 Apr. 19];150(3738):w20348. Available from: https://smw.ch/index.php/smw/article/view/2868

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Most read articles by the same author(s)

Philip Bruggmann, Oliver Senn, Anja Frei, Milo A. Puhan, Jan Fehr, Luis Falcato, High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study , Swiss Medical Weekly: Vol. 152 No. 0102 (2022)
Sarah Blach, Christian Schaetti, Philip Bruggmann, Francesco Negro, Homie Razavi, Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland , Swiss Medical Weekly: Vol. 149 No. 1112 (2019)
Urs Rusch, Sarah Robbins, Homie Razavi, Pietro Vernazza, Sarah Blach, Philip Bruggmann, Beat Müllhaupt, Francesco Negro, David Semela, Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions , Swiss Medical Weekly: Vol. 149 No. 0304 (2019)
Philip Bruggmann, Francesco Negro, Florian Bihl, Sarah Blach, Daniel Lavanchy, Beat Müllhaupt, Homie Razavi, David Semela, Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland , Swiss Medical Weekly: Vol. 145 No. 4950 (2015)
Philip Bruggmann, Sarah Blach, Pierre Deltenre, Jan Fehr, Roger D. Kouyos, Daniel Lavanchy, Beat Müllhaupt, Andri Rauch, Homie Razavi, Patrick Schmid, David Semela, Marcel Stöckle, Franco Negro, Hepatitis C virus dynamics among intravenous drug users suggest that an annual treatment uptake above 10% would eliminate the disease by 2030 , Swiss Medical Weekly: Vol. 147 No. 4546 (2017)

<< < 1 2

[1] Keiser O, Giudici F, Müllhaupt B, Junker C, Dufour JF, Moradpour D, et al.; Swiss Hepatitis C Cohort Study and the Swiss National Cohort. Trends in hepatitis C-related mortality in Switzerland. J Viral Hepat. 2018;25(2):152–60. doi:.https://doi.org/10.1111/jvh.12803

[2] Schürch S, Fux C, Dehler S, Conen A, Knuchel J, Friedl A, et al. Management of hepatitis C in opioid agonist therapy patients of the Swiss canton Aargau within and outside the cohort study. Swiss Med Wkly. 2020.;150:w20317. doi:. https://doi.org/10.4414/smw.2020.20317

[3] Beck T, Bruggmann P, Haemmig R, Caflisch C, Falcato L, Fink A, et al. Medizinische Empfehlungen für Opioidagonistentherapie (OAT) bei Opioidabhängigkeits-Syndrom 2020. Bern: SSAM; 2020.

[4] Federal Office of Public Health Switzerland. Hepatitis C bei Drogenkonsumierenden. Richtlinien mit settingsspezifischen Factsheets. Bern: 2019. https://www.infodrog.ch/files/content/hepc_de/richtlinien-hepatitis-c-drogen-de-2019.pdf

[5] Kind J, Maeschli B, Bruggmann P. Im Schatten von HIV: Das “Aschenbrödel” Hepatitis C. Suchtmedizin. 2019;21(3):103–10.

[6] Müller D, Dittli J, Eder J, Ettlin E, Janiak C, Stöckli H. Motion 19.3743: Die Eliminierung von Hepatitis gehört in ein Nationales Programm sexuell und blutübertragbarer Infektionskrankheiten. In: EDI, editor. Bern: Die Bundesversammlung - das Schweizer Parlement; 2019.

[7] Hepatitis Schweiz. The HepCare Project: Swiss Hepatitis; 2020: www.hepcare.ch.